We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

143 hedge funds and large institutions have $687M invested in Pliant Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 33

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

11% more call options, than puts

Call options by funds: $3.75M | Put options by funds: $3.37M

6% more funds holding

Funds holding: 135 → 143 (+8)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2.3% less ownership

Funds ownership: 108.21% → 105.91% (-2.3%)

29% less capital invested

Capital invested by funds: $971M → $687M (-$284M)

Holders
143
Holders Change
+8
Holders Change %
+5.93%
% of All Funds
2.07%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
28
Increased
50
Reduced
33
Closed
19
Calls
$3.75M
Puts
$3.37M
Net Calls
+$373K
Net Calls Change
+$1.08M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$10.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.29M
3
BlackRock
BlackRock
New York
+$4.08M
4
Morgan Stanley
Morgan Stanley
New York
+$3.74M
5
CS
Candriam SCA
Luxembourg
+$3.68M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$16.4M
2
Capital International Investors
Capital International Investors
California
-$14.9M
3
LCM
Laurion Capital Management
New York
-$12.6M
4
Franklin Resources
Franklin Resources
California
-$6.6M
5
Ameriprise
Ameriprise
Minnesota
-$5.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$5.13M -$234K -18,124 -4%
Charles Schwab
27
Charles Schwab
California
$4.7M +$91.5K +7,096 +2%
Citadel Advisors
28
Citadel Advisors
Florida
$4.63M -$16.4M -1,271,034 -75%
RSCM
29
Rock Springs Capital Management
Maryland
$4.14M – – –
Axa
30
Axa
France
$3.73M +$2.51K +195 +0.1%
Barclays
31
Barclays
United Kingdom
$3.69M -$222K -17,221 -5%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$3.28M +$66.4K +5,152 +2%
MGB
33
Mass General Brigham
Massachusetts
$3.1M – – –
ACH
34
ArrowMark Colorado Holdings
Colorado
$3.02M – – –
SFM
35
Sphera Funds Management
Israel
$2.78M – – –
Renaissance Technologies
36
Renaissance Technologies
New York
$2.72M +$2.29M +177,469 +234%
Two Sigma Investments
37
Two Sigma Investments
New York
$2.64M +$1.79M +138,548 +129%
Jane Street
38
Jane Street
New York
$2.55M +$1.4M +108,586 +84%
CC
39
Checkpoint Capital
California
$2.5M +$2.99M +232,200 New
Bank of New York Mellon
40
Bank of New York Mellon
New York
$2.46M +$382K +29,629 +15%
Capital International Investors
41
Capital International Investors
California
$2.42M -$14.9M -1,152,330 -84%
Goldman Sachs
42
Goldman Sachs
New York
$2.29M -$3.73M -289,333 -58%
N
43
Nuveen
North Carolina
$2.08M -$242K -18,801 -9%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$2.04M +$518K +40,200 +27%
TI
45
Trexquant Investment
Connecticut
$1.71M +$2.05M +158,700 New
UBS Group
46
UBS Group
Switzerland
$1.64M -$2.74M -212,862 -58%
RHJA
47
Rice Hall James & Associates
California
$1.37M +$1.65M +127,634 New
EAM
48
Exome Asset Management
New York
$1.33M +$1.6M +124,000 New
RPAM
49
Rhenman & Partners Asset Management
Sweden
$1.29M -$322K -25,000 -17%
UBS AM
50
UBS AM
Illinois
$1.26M +$585K +45,363 +63%
1
2
3 4 5

PLRX Hedge Fund Activity: Q2 2024 in Review

143 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2024, worth a combined $687M — down 29% from $971M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PLRX positions and 19 closed out — a net gain of 9 holders — while 50 added to existing stakes and 33 trimmed.

The largest buyer was Great Point Partners, adding an estimated $10.1M. The largest seller was Citadel Advisors, cutting an estimated $16.4M.

  • 143 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2024, up from 135 in Q1 2024.
  • Funds reported $687M of Pliant Therapeutics stock for Q2 2024, down 29% quarter-over-quarter.
  • 28 funds opened new Pliant Therapeutics positions in Q2 2024 and 19 closed out, a net change of +9 holders.
  • The largest Pliant Therapeutics buyer in Q2 2024 was Great Point Partners, an estimated $10.1M added.
  • The largest Pliant Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $16.4M sold.

Based on aggregated 13F filings for Q2 2024.